Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )
4 Jun 2022

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
4 Jun 2022

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA
N-803-BCG combination shows promising results in BCG-unresponsive NMIBC ( Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA )
4 Jun 2022

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Dr Cary Adams - Chief Executive Officer, UICC
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, UICC )
4 Jun 2022

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - Cancer Control Officer, WHO
ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - Cancer Control Officer, WHO )
4 Jun 2022